6:03 AM ET
8-K
Clinical Trial Data
Zenas BioPharma Clinical Trial Data
Zenas BioPharma announced new data from its Phase 3 INDIGO trial and open-label extension for obexelimab in patients with IgG4-related disease (IgG4-RD). The findings demonstrated sustained clinical activity with a 93% probability of remaining flare-free over 12 months and a significant reduction in cumulative glucocorticoid toxicity compared to placebo.